Allogene Therapeutics, Inc.

NasdaqGS:ALLO Stock Report

Market Cap: US$286.2m

Allogene Therapeutics Management

Management criteria checks 3/4

Allogene Therapeutics' CEO is David Chang, appointed in Jun 2018, has a tenure of 7.33 years. total yearly compensation is $4.48M, comprised of 16.2% salary and 83.8% bonuses, including company stock and options. directly owns 2.58% of the company’s shares, worth $7.38M. The average tenure of the management team and the board of directors is 2.5 years and 7.5 years respectively.

Key information

David Chang

Chief executive officer

US$4.5m

Total compensation

CEO salary percentage16.15%
CEO tenure7.3yrs
CEO ownership2.6%
Management average tenure2.5yrs
Board average tenure7.5yrs

Recent management updates

Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now

Jun 12
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now

Recent updates

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Aug 14

Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now

Jun 12
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now

Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation

Apr 02
Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Feb 25

Allogene Therapeutics: Showing Promise Despite Some Shaky Safety

Dec 10

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

Nov 22
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 27

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Jun 12

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Apr 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Jun 09
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Feb 22
We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

CEO Compensation Analysis

How has David Chang's remuneration changed compared to Allogene Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$237m

Mar 31 2025n/an/a

-US$252m

Dec 31 2024US$4mUS$724k

-US$258m

Sep 30 2024n/an/a

-US$283m

Jun 30 2024n/an/a

-US$279m

Mar 31 2024n/an/a

-US$292m

Dec 31 2023US$14mUS$724k

-US$327m

Sep 30 2023n/an/a

-US$344m

Jun 30 2023n/an/a

-US$365m

Mar 31 2023n/an/a

-US$361m

Dec 31 2022US$15mUS$724k

-US$340m

Sep 30 2022n/an/a

-US$313m

Jun 30 2022n/an/a

-US$308m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$10mUS$695k

-US$182m

Sep 30 2021n/an/a

-US$251m

Jun 30 2021n/an/a

-US$239m

Mar 31 2021n/an/a

-US$229m

Dec 31 2020US$8mUS$675k

-US$316m

Sep 30 2020n/an/a

-US$243m

Jun 30 2020n/an/a

-US$227m

Mar 31 2020n/an/a

-US$207m

Dec 31 2019US$11mUS$600k

-US$185m

Sep 30 2019n/an/a

-US$154m

Jun 30 2019n/an/a

-US$147m

Mar 31 2019n/an/a

-US$240m

Dec 31 2018US$13mUS$362k

-US$212m

Compensation vs Market: David's total compensation ($USD4.48M) is above average for companies of similar size in the US market ($USD1.51M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Chang (65 yo)

7.3yrs
Tenure
US$4,482,208
Compensation

Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc. since June 2018. He serves as Board Chair of IconOVir Bio Inc. He served as Chief Medic...

Leadership Team

NamePositionTenureCompensationOwnership
Arie Belldegrun
Co-Founder & Executive Chairman7.9yrsUS$2.97m2.63%
$ 7.5m
David Chang
Co-Founder7.3yrsUS$4.48m2.58%
$ 7.4m
Joshua Kazam
Co-Founder & Directorno dataUS$352.65k0.14%
$ 391.0k
Zachary Roberts
Executive VP of Research & Development and Chief Medical Officer2.8yrsUS$2.22m0.046%
$ 131.5k
Geoffrey Parker
Executive VP & CFO2yrsno data0.59%
$ 1.7m
Benjamin Beneski
Senior VP & Chief Technical Officerless than a yearno data0.098%
$ 281.9k
Earl Douglas
Senior VP2.2yrsno data0.26%
$ 758.3k
Susan Lundeen
Chief People Officer3.4yrsno datano data
Christine Cassiano
Executive VP2.8yrsno datano data
Annie Yoshiyama
SVP & Corporate Controller1.3yrsno data0.024%
$ 70.1k
2.5yrs
Average Tenure
59yo
Average Age

Experienced Management: ALLO's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Arie Belldegrun
Co-Founder & Executive Chairman7.9yrsUS$2.97m2.63%
$ 7.5m
David Chang
Co-Founder7.3yrsUS$4.48m2.58%
$ 7.4m
Joshua Kazam
Co-Founder & Director7.9yrsUS$352.65k0.14%
$ 391.0k
Franz Humer
Lead Independent Director7.5yrsUS$421.71k0.12%
$ 357.0k
Owen Witte
Independent Director7.5yrsUS$363.65k0.13%
$ 377.8k
Malcolm Brenner
Member of Scientific Advisory Board6.4yrsno datano data
Todd Sisitsky
Independent Director7.4yrsno datano data
Deborah Messemer
Independent Director7.1yrsUS$370.00k0.048%
$ 138.6k
Matthew Porteus
Member of Scientific Advisory Boardno datano datano data
Donald Kohn
Member of Scientific Advisory Boardno datano datano data
Antonius Schumacher
Chairman of Scientific Advisory Boardno datano datano data
John DeYoung
Independent Director7.5yrsno datano data
7.5yrs
Average Tenure
66yo
Average Age

Experienced Board: ALLO's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 11:51
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allogene Therapeutics, Inc. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Shanshan XuBerenberg
Jason Matthew GerberryBofA Global Research